Long-term follow-up of patients who received recombinant human granulocyte-macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid malignancy

J. Nemunaitis, J. W. Singer, C. D. Buckner, T. Mori, J. Laponi, R. Hill, R. Storb, K. M. Sullivan, J. A. Hansen, F. R. Appelbaum

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

Twenty-seven patients with lymphoid neoplasia who underwent autologous bone marrow transplant (BMT) and who had received recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) were followed in order to examine the potential long-term consequences of rhGM-CSF. rhGM-CSF (15-240 μg/m2/day) was given daily either for 14 or 21 days after marrow infusion. All surviving patients who remained in remission had stable marrow graft function. The actuarial survival rate was 45% and the relapse incidence was 50% at a median of 774 days after autologous BMT. These findings suggest that treatment with rhGM-CSF does not have profound adverse long-term consequences.

Original languageEnglish (US)
Pages (from-to)49-52
Number of pages4
JournalBone marrow transplantation
Volume7
Issue number1
StatePublished - Jan 1 1991

    Fingerprint

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Nemunaitis, J., Singer, J. W., Buckner, C. D., Mori, T., Laponi, J., Hill, R., Storb, R., Sullivan, K. M., Hansen, J. A., & Appelbaum, F. R. (1991). Long-term follow-up of patients who received recombinant human granulocyte-macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid malignancy. Bone marrow transplantation, 7(1), 49-52.